English
Home > Products > 4-Fluoroanisole

China 4-Fluoroanisole Factory

Our corporation has been specializing in brand strategy. Customers' gratification is our greatest advertising. We also source OEM company for 4-Fluoroanisole,CAS NO 459-60-9,459-60-9, We attend seriously to produce and behave with integrity, and with the favor of consumers at your house and abroad during the xxx industry.
4-Fluoroanisole, We also provide OEM service that caters to your specific needs and requirements. With a strong team of experienced engineers in hose design and development, we value every opportunity to provide best products for our customers.

Related Products

Hot Products

  • Pravastatin sodium

    Pravastatin sodium

    Product Name:Pravastatin sodium
    Molecular Formula:C23H36NaO7
    Molecular Weight;447.52
    CAS Registry Number;81131-70-6
  • Everolimus

    Everolimus

    Product Name:Everolimus
    Molecular Formula:C53H83NO14
    Molecular Weight;958.22
    CAS Registry Number;159351-69-6
  • 5-(1H-Pyrrol-1-yl)-2-mercaptobenzimidazole

    5-(1H-Pyrrol-1-yl)-2-mercaptobenzimidazole

    Product Name:5-(1H-Pyrrol-1-yl)-2-mercaptobenzimidazole
    Molecular Formula:C11H9N3S
    Molecular Weight:215.27
    CAS Registry Number:172152-53-3
  • 5-(4-Nitrophenyl)-2-furaldehyde

    5-(4-Nitrophenyl)-2-furaldehyde

    Product Name:5-(4-Nitrophenyl)-2-furaldehyde
    Molecular Formula:C11H7NO4
    Molecular Weight:217.18
    CAS Registry Number:7147-77-5
  • Beleodaq

    Beleodaq

    Product Name:Beleodaq
    Molecular Formula:C15H14N2O4S
    Molecular Weight;318.35
    CAS Registry Number;866323-14-0
  • Azacytidine

    Azacytidine

    Product Name:Azacytidine
    Molecular Formula:C8H12N4O5
    Molecular Weight;244.2
    CAS Registry Number;320-67-2
  • Related Blog
  • Reviews

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept